These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 16998755)

  • 21. Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications.
    Dziadkowiak E; Nowakowska-Kotas M; Rałowska-Gmoch W; Budrewicz S; Koszewicz M
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
    Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
    Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
    van Nes SI; Vanhoutte EK; van Doorn PA; Hermans M; Bakkers M; Kuitwaard K; Faber CG; Merkies IS
    Neurology; 2011 Jan; 76(4):337-45. PubMed ID: 21263135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on therapy of chronic immune-mediated neuropathies.
    Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E
    Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies in immune-mediated inflammatory neuropathies.
    Martín-Aguilar L; Pascual-Goñi E; Querol L
    Med Clin (Barc); 2019 Nov; 153(9):360-367. PubMed ID: 31443948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies.
    Lim JP; Devaux J; Yuki N
    Autoimmun Rev; 2014 Oct; 13(10):1070-8. PubMed ID: 25172243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immune-mediated neuropathies].
    Stoll G; Reiners K
    Nervenarzt; 2016 Aug; 87(8):887-98. PubMed ID: 27474733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report.
    Alexander KJ; Alshubaili AF; Santhamoorthy P; Sharafuddin KM
    Med Princ Pract; 2008; 17(5):422-4. PubMed ID: 18685286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-Mediated Neuropathies.
    Gwathmey KG; Smith AG
    Neurol Clin; 2020 Aug; 38(3):711-735. PubMed ID: 32703478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of inflammatory and paraproteinemic neuropathies.
    Monaco S; Turri E; Zanusso G; Maistrello B
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Jun; 4(2):141-8. PubMed ID: 15180454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of immune-mediated inflammatory neuropathies.
    Hadden RD; Hughes RA
    Curr Opin Neurol; 1999 Oct; 12(5):573-9. PubMed ID: 10590894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of dys-immune neuropathies.
    Nobile-Orazio E
    J Neurol; 2005 Apr; 252(4):385-95. PubMed ID: 15834625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-mediated neuropathies.
    Kieseier BC; Mathey EK; Sommer C; Hartung HP
    Nat Rev Dis Primers; 2018 Oct; 4(1):31. PubMed ID: 30310069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Guillain-Barré syndrome and CIDP.
    van Doorn PA
    J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immune-mediated neuropathies: pathophysiology and management].
    Tian YY; Yuan PP; Wang XG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Sep; 58(9):1432-1437. PubMed ID: 39290027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.
    Querol L; Lleixà C
    Neurotherapeutics; 2021 Oct; 18(4):2222-2235. PubMed ID: 34549385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune diseases of the peripheral nervous system.
    Kieseier BC; Lehmann HC; Meyer Zu Hörste G
    Autoimmun Rev; 2012 Jan; 11(3):191-5. PubMed ID: 21621007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IVIg-induced acute polyneuroradiculitis in a patient with CIDP?
    Krasenbrink I; Kaps M; Blaes F
    Eur J Neurol; 2007 May; 14(5):e9. PubMed ID: 17437603
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.
    Mathis S; Vallat JM; Magy L
    Immunotherapy; 2016 Feb; 8(2):165-78. PubMed ID: 26809024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of inflammatory neuropathies.
    Hadden RD; Hughes RA
    J Neurol Neurosurg Psychiatry; 2003 Jun; 74 Suppl 2(Suppl 2):ii9-ii14. PubMed ID: 12754323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.